To evaluate the antitumor efficacy of vvDD-IL-23, we injected PBS, vvDD or vvDD-IL-23 at the dose of 2×108 PFU per mouse i.p. to treat B6 mice bearing five-day old peritoneal murine colon cancer MC38-luc; survival results demonstrated that vvDD-IL-23 elicited significantly potent antitumor effects compared with PBS or vvDD treatment (Figure 2A). Here, IL23A is linked to colonic neoplasm.